diphenylamine has been researched along with Carcinoma, Squamous Cell in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, W; Jin, M; Kong, D; Li, H; Lin, P; Liu, Y; Peng, X; Qiu, Y; Wang, R; Zhang, Z; Zhu, S | 1 |
| Abe, R; Hata, H; Imafuku, K; Kitamura, S; Shimizu, H; Yanagi, T | 1 |
| Bi, C; Chng, WJ; Chua, KN; Goh, BC; Ho, J; Huynh, H; Kong, LR; Ng, HC; Nga, ME; Ong, WR; Pang, YH; Sim, WJ; Soo, RA; Thiery, JP | 1 |
| Carlson, SG; Chen, Z; Cheng, H; Coupar, JF; Eytan, DF; Mohan, S; Pierce, ML; Shah, S; Van Waes, C; Vander Broek, R; Zhang, J | 1 |
| Affolter, A; Freier, K; Hess, J; Lorenz, K; Muller, MF; Perner, S; Plinkert, PK; Sharma, S; Sommer, K; Stenzinger, A; Weber, KJ; Weichert, W; Wolf, J; Wolf, T; Zaoui, K | 1 |
| Bazhenova, L; Cohen, RB; Eisenberg, PD; Gadgeel, SM; Haura, EB; Larson, TG; Miller, VA; Ricart, AD; Selaru, P; Stella, PJ; Wilner, KD | 1 |
1 trial(s) available for diphenylamine and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzamides; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diphenylamine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
5 other study(ies) available for diphenylamine and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphenylamine; Drug Synergism; Humans; Hypopharyngeal Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Retrospective Studies; Signal Transduction; Sulfonamides | 2019 |
Drp1 regulates mitochondrial morphology and cell proliferation in cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Benzamides; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Dynamins; Female; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; GTP Phosphohydrolases; Humans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Middle Aged; Mitochondria; Mitochondrial Dynamics; Mitochondrial Proteins; Neoplasm Staging; Phosphorylation; Quinazolinones; RNA Interference; RNA, Small Interfering; Skin Neoplasms; Xenograft Model Antitumor Assays | 2017 |
MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Diphenylamine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Proteomics; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Son of Sevenless Proteins; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cytokines; Diphenylamine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Genes, Reporter; Head and Neck Neoplasms; Humans; Inflammation Mediators; Mitogen-Activated Protein Kinase Kinases; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcriptional Activation; Triazines; Xenograft Model Antitumor Assays | 2015 |
Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer.
Topics: Adult; Aged; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Female; Head and Neck Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Phosphorylation; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2016 |